It is used to prevent catheter-associated urinary tract infections (CAUTI) in people with long-term indwelling catheters. The innovative aspects are that it uses surface acoustic wave technology to prevent the attachment of bacteria to the surface of catheters. The intended place in therapy would be as well as existing catheter products to help prevent infection in people with indwelling catheters.
 
Status In progress
Process MT
ID number 476

Provisional Schedule

Scope published 14 May 2021
Committee meeting: 1 20 August 2021
Draft guidance: 1 13 September 2021 - 11 October 2021
Committee meeting: 2 10 December 2021
Resolution 31 January 2022
Expected publication 15 March 2022

Email enquiries

Stakeholders

External assessment group CEDAR
Manufacturers NanoVibronix Ltd
Others Association of British Healthcare Industries (ABHI)
  Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)
  Boston Scientific
  Department of Health and Social Care
  Devices for Dignity
  Greater Manchester Health & Social Care Partnership
  Healthcare Improvement Scotland
  HealthTech Alliance
  Johnson & Johnson Medical Ltd
  Medical Technology Group
  Medicines and Healthcare Products Regulatory Agency
  NHS England
  NHS England
  NHS England
  NHS England
  NHS England
  The British In Vitro Diagnostics Association (BIVDA)
  NHS Digital
  NHS Digital
  University of Manchester Wounds Research Group

Timeline

Key events during the development of the guidance:

Date Update
24 March 2021 Stakeholder registration opens

For further information on how we develop guidance, please see our page about NICE medical technologies guidance